Deterioration of hematologic parameters in lymphoma patients is often attributed to disease progression, comorbidities, or treatment effects. Second primary malignancies occur at increased frequency in CLL and must also be considered. 
| INTRODUCTION
A 73-year-old woman with a long-standing history of untreated chronic lymphocytic leukemia (CLL) presented with fatigue and progressive anemia. A bone marrow biopsy was performed for suspicion of disease progression and exclusion of alternative conditions.
Her peripheral blood showed atypical lymphocytes with dimorphic cytologic features ( Figure The risk of developing a second primary malignancy is more than twice as high in patients with CLL than those without and must be considered in the setting of emerging cytopenias.
1 Among secondary hematologic malignancies, most of this excess risk is due to additional non-Hodgkin lymphomas. 2 In this case, the patient's worsening anemia was attributed to the combination of her new secondary non-Hodgkin lymphoma in composite with her known CLL.
